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Background	  of	  the	  Biotechnology	  Industry	  
•  Revenues	  of	  $400B	  in	  2012	  
•  Decelerating	  growth	  rate	  
•  FDA	  regulation	  is	  a	  critical	  factor	  
•  Biggest	  growth	  is	  occurring	  in	  Oncology	  and	  Central	  Nervous	  System	  
	  
Background	  of	  Amgen	  
•  Founded	  in	  1980	  
•  $17.27B	  in	  Revenues	  in	  2012	  
•  4%	  Market	  Share	  
Background	  of	  Central	  Nervous	  System	  Market	  
Segment	  
•  Deals	  with	  diseases	  aﬀecting	  a	  person’s	  brain,	  spinal	  cord,	  and	  neurons	  
•  Primary	  drugs	  deal	  with	  Alzheimer’s,	  Parkinson’s,	  Epilepsy,	  and	  Depression	  
Introduction	  to	  CONCUSSYN 	  	  
By:	  Justin	  Deats	  
•  Concussions	  are	  a	  type	  of	  Traumatic	  Brain	  Injury	  (TBI)	  
•  Estimated	  between	  1.6MM	  –	  3.8MM	  per	  year	  	  
•  Most	  go	  unreported	  –	  around	  50%	  
•  Cause	  Mild	  Cognitive	  Impairments	  (MCI’s)	  and	  Chronic	  Traumatic	  
Encephalopathy	  (CTE)	  when	  suﬀered	  more	  than	  once.	  
•  Likelihood	  of	  another	  concussion	  increases	  with	  each	  concussion	  
•  Most	  commonly	  sustained	  in	  sports,	  increasing	  number	  in	  war	  
Critical	  Issues	  
By:	  Justin	  Deats	  
•  11.9%	  multiple	  concussion	  rate	  in	  High	  School	  
•  Cincinnati	  area	  study	  said	  they	  would	  play	  with	  symptoms	  
•  More	  exposure	  to	  these	  injuries	  because	  they	  start	  at	  a	  young	  age	  
•  More	  exposure	  means	  increased	  risk	  of	  CTE	  
•  Currently	  no	  treatment	  for	  CTE	  because	  no	  deﬁnitive	  pre-­‐mortem	  diagnosis	  
•  UCLA	  Study	  can	  detect	  Hyperphosphorylated	  Tau	  Proteins	  in	  living	  people	  using	  their	  
chemical	  market	  “FDDNP”	  
•  Crucial	  for	  the	  development	  of	  CTE	  treatment	  
Recommended	  Strategies	  
By:	  Justin	  Deats	  
•  Use	  Diaminothyazoles	  CDK5	  and	  GSK3β	  inhibitors	  to	  reduce	  
phosphorylization	  and	  restore	  learning	  and	  memory	  abilities	  
•  Maintain	  proper	  function	  of	  axonal	  microtubules	  
•  CONCUSSYN	  will	  be	  use	  to	  treat	  this	  early	  on	  in	  concussion	  victims	  
	  
Justiﬁcation 	  	  
By:	  Justin	  Deats	  
•  First	  product	  to	  speciﬁcally	  treat	  CTE	  and	  reverse	  some	  of	  the	  eﬀects	  that	  it	  
has	  
•  Previously,	  the	  only	  treatment	  was	  avoiding	  high	  risk	  atmospheres	  
•  Amgen	  needs	  to	  continually	  improve	  to	  increase	  market	  share	  and	  
competitiveness	  
Implementation	  Plan	  
By:	  Justin	  Deats	  
•  Begin	  Development	  in	  2013	  
•  R&D,	  Clinical	  Trials,	  and	  FDA	  approval	  are	  expected	  to	  take	  6	  years	  
•  Release	  product	  in	  2019	  
•  Initial	  $400MM	  spent	  of	  PP&E	  
•  5	  &	  10	  mg	  tablets	  taken	  once	  daily,	  1-­‐month	  prescriptions,	  $333.33	  per	  
prescription	  or	  $4,000	  annually	  
Product,	  Process	  and	  Service	  
Development	  
By:	  Justin	  Deats	  
•  Test	  on	  animals	  to	  make	  sure	  its	  safe	  for	  humans	  to	  take	  
•  Identify	  potential	  risks	  of	  the	  drug	  
•  Submit	  Investigative	  New	  Drug	  Application	  (INDA)	  to	  FDA	  
•  Conduct	  Phases	  1-­‐3	  of	  Clinical	  Trials	  
•  Duration	  of	  about	  5	  years	  
•  Submit	  New	  Drug	  Application	  (NDA)	  to	  FDA	  
•  FDA	  conducts	  further	  testing	  	  
•  If	  beneﬁts	  outweigh	  the	  risks,	  it	  is	  approved	  	  
•  Duration	  of	  about	  2.5	  years	  
Research	  and	  Development	  Expenditures	  
By:	  Justin	  Deats	  
•  Pivotal	  in	  the	  foundation	  of	  new	  product	  
•  Study	  shows	  5%	  increase	  in	  R&D	  for	  Biotech	  companies	  resulted	  in	  24%	  
increase	  in	  the	  average	  revenues	  
•  CONCUSSYN	  initial	  R&D	  expenditure	  is	  $118.08MM	  
Capacity	  Requirements 	  	  
By:	  Justin	  Deats	  
•  Amgen	  needs	  to	  build	  new	  facilities	  for	  the	  production	  of	  CONCUSSYN	  
•  Initial	  capital	  will	  be	  invested	  in	  buildings,	  laboratory	  equipment,	  furniture	  and	  other	  
items	  
•  Initial	  investment	  will	  total	  $400MM	  in	  PP&E	  
•  This	  will	  increase	  over	  the	  life	  of	  the	  product	  
•  PP&E	  expected	  useful	  life	  is	  18	  years,	  and	  will	  depreciate	  each	  year	  
Strategic	  Fit	  
By:	  Justin	  Deats	  
•  Enbrel	  is	  Amgen’s	  Blockbuster	  drug	  in	  CNS	  Market	  Segment	  
•  Splits	  proﬁt	  50-­‐50	  with	  Pﬁzer	  
•  Threatened	  by	  “Triple	  Therapy”	  treatment	  
•  CONCUSSYN	  will	  help	  strengthen	  its	  position	  in	  CNS	  Market	  Segment	  
•  Only	  treatment	  for	  CTE	  
Growth	  Opportunities	  
By:	  Justin	  Deats	  
•  Large	  number	  of	  concussions	  each	  year	  (1.6-­‐3.8MM	  estimated)	  
•  Currently	  no	  treatment	  for	  CTE	  
•  New	  methods	  of	  detecting	  Hyperphosphorylation	  in	  the	  brain	  
Financial	  Analysis	  
By:	  Justin	  Deats	  
Net Sales Forecast (2013-2031) 18 Years 
Company:	  Amgen,	  CNS	  Market	  Segment,	  Traumatic	  Brain	  Injury	  Treatment	  –	  Strategy:	  CONCUSSYN	  
By:	  Justin	  Deats	  
Source:	  	  Seshan,	  V.	  PH.D.	  Strategic	  Management,	  Financial	  Analysis,	  and	  Cash	  Flow.	  Thirteenth	  Edition.	  Cengage,	  Mason,	  OH.,	  Book	  and	  CD-­‐Rom,	  Page	  156.	  2013.	  
Year Total Units Sold Price Sales ($MM) Growth Rate Cumulative ($MM)
2013 -              -       -       -       -                   
2014 -              -       -       -       -                   
2015 -              -       -       -       -                   
2016 -              -       -       -       -                   
2017 -              -       -       -       -                   
2018 -              -       -       -       -                   
2019 119,399 4000 477.60 -       477.60
2020 194,562 4000 778.25 62.95% 1,255.85
2021 287,554 4000 1,150.22 47.80% 2,406.06
2022 387,087 4000 1,548.35 34.61% 3,954.41
2023 508,205 4000 2,032.82 31.29% 5,987.23
2024 658,641 4000 2,634.56 29.60% 8,621.80
2025 838,566 3800 3,186.55 20.95% 11,808.35
2026 1,012,670 3800 3,848.15 20.76% 15,656.49
2027 1,155,458 3800 4,390.74 14.10% 20,047.23
2028 1,237,106 3800 4,701.00 7.07% 24,748.24
2029 1,343,572 3800 5,105.57 8.61% 29,853.81
2030 1,416,222 3700 5,240.02 2.63% 35,093.83
2031 1,473,445 3700 5,451.75 4.04% 40,545.58
18 Year Depreciation Schedule (2013-2022) 
Company:	  Amgen,	  CNS	  Market	  Segment,	  Traumatic	  Brain	  Injury	  Treatment	  –	  Strategy:	  CONCUSSYN	  
By:	  Justin	  Deats 
Calc. of Init. Strat. Cap. Expend.
Initial Capital Expenditure 2013 ($MM) 400     
Useful Life of Capital 18 Years
Add. Cap. Expend.
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
Property, Plant and Equipment 400     448     493     537     575     621     664     697     725     754     
Growth Percent of Capital Expenditures 12% 10% 9% 7% 8% 7% 5% 4% 4%
Additional Capital Expenditures 48      45      44      38      46      43      33      28      29      
Dep. on Add. Cap. Expend. Outlay
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
Depreciation on Additional Capital Expenditures -      -      -      -      -      -      -      -      -      -      
2.67    2.67    2.67    2.67    2.67    2.67    2.67    2.67    2.67    
2.49    2.49    2.49    2.49    2.49    2.49    2.49    2.49    
2.46    2.46    2.46    2.46    2.46    2.46    2.46    
2.09    2.09    2.09    2.09    2.09    2.09    
2.55    2.55    2.55    2.55    2.55    
2.41    2.41    2.41    2.41    
1.84    1.84    1.84    
1.55    1.55    
1.61    
Depreciation on Additional Capital Expenditures -      2.67    5.16    7.62    9.71    12.26   14.68   16.52   18.07   19.68   
Depreciation on Initial Strategic Outlay 22.22   22.22   22.22   22.22   22.22   22.22   22.22   22.22   22.22   22.22   
Total Depreciation 22.22   24.89   27.38   29.84   31.93   34.49   36.90   38.74   40.29   41.91   
Total Strategic Property, Plant and Equipment 400     448     493     537     575     621     664     697     725     754     
Accumulated Depreciation on Strategic P,P&E 22.22   47.11   74.49   104.33 136.26 170.75 207.65 246.39 286.68 328.59 
Net Property, Plant and Equipment 377.78 400.89 418.31 432.82 438.49 449.99 456.54 451.00 438.61 425.71 Source:	  	  Seshan,	  V.	  PH.D.	  Strategic	  Management,	  Financial	  Analysis,	  and	  Cash	  Flow.	  Thirteenth	  Edition.	  Cengage,	  Mason,	  OH.,	  Book	  and	  CD-­‐Rom,	  Pages	  157-­‐161.	  2013.	  
18 Year Depreciation Schedule (2023-2031) 
Company:	  Amgen,	  CNS	  Market	  Segment,	  Traumatic	  Brain	  Injury	  Treatment	  –	  Strategy:	  CONCUSSYN	  
By:	  Justin	  Deats 
$MM
Add. Cap. Expend.
2023 2024 2025 2026 2027 2028 2029 2030 2031
Property, Plant and Equipment 777      808      840      866     892     909      946     974     994
Growth Percent of Capital Expenditures 3% 4% 4% 3% 3% 2% 4% 3% 2%
Additional Capital Expenditures 23        31        32       25       26       18        36       28       19
Dep. on Add. Cap. Expend. Outlay
2023 2024 2025 2026 2027 2028 2029 2030 2031
Depreciation on Additional Capital Expenditures -       -       -      -      -      -       -      -      -      
2.67     2.67     2.67     2.67     2.67     2.67     2.67     2.67    2.67     
2.49     2.49     2.49     2.49     2.49     2.49     2.49     2.49    2.49     
2.46     2.46     2.46     2.46     2.46     2.46     2.46     2.46    2.46     
2.09     2.09     2.09     2.09     2.09     2.09     2.09     2.09    2.09     
2.55     2.55     2.55     2.55     2.55     2.55     2.55     2.55    2.55     
2.41     2.41     2.41     2.07     2.07     2.07     2.07     2.07    2.07     
1.84     1.84     1.84     1.84     1.84     1.84     1.84     1.84    1.84     
1.55     1.55     1.55     1.55     1.55     1.55     1.55     1.55    1.55     
1.61     1.61     1.61     1.61     1.61     1.61     1.61     1.61    1.61     
1.26     1.26     1.26     1.26     1.26     1.26     1.26     1.26    1.26     
1.73     1.73     1.73     1.73     1.73     1.73     1.73    1.73     
1.80     1.80     1.80     1.80     1.80     1.80    1.80     
1.40     1.40     1.40     1.40     1.40    1.40     
1.44     1.44     1.44     1.44    1.44     
0.99     0.99     0.99    0.99     
2.02     2.02    2.02     
1.58    1.58     
1.08     
Depreciation on Additional Capital Expenditures 20.94    22.67    24.46   25.52   26.96   27.95    29.97   31.55   32.63   
Depreciation on Initial Strategic Outlay 22.22    22.22    22.22   22.22   22.22   22.22    22.22   22.22   -
Total Depreciation 43.16    44.89    46.68   47.74   49.18   50.17    52.19   53.77   32.63   
Total Strategic Property, Plant and Equipment 777      808      840      866     892     909      946     974     994     
Accumulated Depreciation on Strategic P,P&E 371.75  416.64  463      511      560     610      663     716     749     
Net Property, Plant and Equipment 405.18  391.37  377.00  354.47  331.25  298.91  283.09  257.69 244.54  Source:	  	  Seshan,	  V.	  PH.D.	  Strategic	  Management,	  Financial	  Analysis,	  and	  Cash	  Flow.	  Thirteenth	  Edition.	  Cengage,	  Mason,	  OH.,	  Book	  and	  CD-­‐Rom,	  Pages	  157-­‐161.	  2013.	  
Pro-Forma Income Statement  (2013-2018) 1st 6 of 18 years 
Company:	  Amgen,	  CNS	  Market	  Segment,	  Traumatic	  Brain	  Injury	  Treatment	  –	  Strategy:	  CONCUSSYN	  
By:	  Justin	  Deats 
Source:	  	  Seshan,	  V.	  PH.D.	  Strategic	  Management,	  Financial	  Analysis,	  and	  Cash	  Flow.	  Thirteenth	  Edition.	  Cengage,	  Mason,	  OH.,	  Book	  and	  CD-­‐Rom,	  Pages	  162-­‐167.	  2013.	  
 $MM 2013 % of Sales 2014 % of Sales 2015 % of Sales 2016 % of Sales 2017 % of Sales 2018 % of Sales
Growth Rate
Net Sales -        0% -       0% -       0% -       0% -       0% -       0%
COGS -        0% -       0% -       0% -       0% -       0% -       0%
Gross Margin -        0% -       0% -       0% -       0% -       0% -       0%
S,G&A 15.57     0% 18.88    0% 21.09    0% 25.15    0% 27.69    0% 32.42    0%
R&D 122.84    0% 125.11  0% 128.53  0% 133.08  0% 134.21  0% 137.63  0%
Depreciation Expense 22.22     0% 24.89    0% 27.38    0% 29.84    0% 31.93    0% 34.49    0%
Operating Expenses 160.63    0% 168.88  0% 177.00  0% 188.07  0% 193.83  0% 204.54  0%
(TCOS) Total Cost of Sales 160.63    0% 168.88  0% 177.00  0% 188.07  0% 193.83  0% 204.54  0%
Operating Income (EBIT) (160.63)   0% (168.88) 0% (177.00) 0% (188.07) 0% (193.83) 0% (204.54) 0%
Taxes -        0% -       0% -       0% -       0% -       0% -       0%
Net Income (160.63)   0% (168.88) 0% (177.00) 0% (188.07) 0% (193.83) 0% (204.54) 0%
Additional Capital Expenditures for capacity growth to support Net Sales
Pro-Forma Income Statement  (2019-2024) 2nd 6 of 18 years 
Company:	  Amgen,	  CNS	  Market	  Segment,	  Traumatic	  Brain	  Injury	  Treatment	  –	  Strategy:	  CONCUSSYN	  
By:	  Justin	  Deats 
Source:	  	  Seshan,	  V.	  PH.D.	  Strategic	  Management,	  Financial	  Analysis,	  and	  Cash	  Flow.	  Thirteenth	  Edition.	  Cengage,	  Mason,	  OH.,	  Book	  and	  CD-­‐Rom,	  Pages	  162-­‐167.	  2013.	  
 $MM 2019 % of Sales 2020 % of Sales 2021 % of Sales 2022 % of Sales 2023 % of Sales 2024 % of Sales
Growth Rate 63% 48% 35% 31% 30%
Net Sales 477.60 100% 778.25 100% 1,150.22 100% 1,548.35 100% 2,032.82 100% 2,634.56 100%
COGS 179.10 38% 311.30 40% 460.09   40% 580.63   38% 762.31   38% 1,053.83 40%
Gross Margin 298.50 63% 466.95 60% 690.13   60% 967.72   63% 1,270.51 63% 1,580.74 60%
S,G&A 39.34   8% 76.93   10% 90.71    8% 108.54   7% 125.58   6% 143.23   5%
R&D 142.18 30% 166.06 21% 192.22   17% 219.52   14% 249.08   12% 283.21   11%
Depreciation Expense 36.90   8% 38.74   5% 40.29    4% 41.91     3% 43.16     2% 44.89     2%
Operating Expenses 218.42 46% 281.73 36% 323.23   28% 369.97   24% 417.82   21% 471.33   18%
(TCOS) Total Cost of Sales 397.52 83% 593.03 76% 783.31   68% 950.60   61% 1,180.13 58% 1,525.15 58%
Operating Income (EBIT) 80.08   17% 185.22 24% 366.90   32% 597.75   39% 852.69   42% 1,109.41 42%
Taxes 23.22   0% 53.71   0% 106.40   9% 173.35   11% 247.28   12% 321.73   12%
Net Income 56.86   12% 131.50 17% 260.50   23% 424.40   27% 605.41   30% 787.68   30%
Additional Capital Expenditures for capacity growth to support Net Sales
Pro-Forma Income Statement  (2025-2031) Last 7 of 18 years 
Company:	  Amgen,	  CNS	  Market	  Segment,	  Traumatic	  Brain	  Injury	  Treatment	  –	  Strategy:	  CONCUSSYN	  
By:	  Justin	  Deats 
Source:	  	  Seshan,	  V.	  PH.D.	  Strategic	  Management,	  Financial	  Analysis,	  and	  Cash	  Flow.	  Thirteenth	  Edition.	  Cengage,	  Mason,	  OH.,	  Book	  and	  CD-­‐Rom,	  Pages	  162-­‐167.	  2013.	  
 $MM 2025 % of Sales 2026 % of Sales 2027 % of Sales 2028 % of Sales 2029 % of Sales 2030 % of Sales 2031 % of Sales
Growth Rate 21% 21% 14% 7% 9% 3% 4%
Net Sales 3,186.55  100% 3,848.15 100% 4,390.74 100% 4,701.00 100% 5,105.57 100% 5,240.02 100% 5,451.75 100%
COGS 1,402.08  44% 1,654.70 43% 1,844.11 42% 1,946.22 41% 2,093.28 41% 2,096.01 40% 2,180.70 40%
Gross Margin 1,784.47  56% 2,193.44 57% 2,546.63 58% 2,754.79 59% 3,012.29 59% 3,144.01 60% 3,271.05 60%
Additional Capital Expenditures for capacity growth to support Net Sales
S,G&A 149.37     5% 165.75   4% 178.53   4% 194.65   4% 201.10   4% 221.12   4% 238.74   4%
R&D 315.19     10% 346.94   9% 391.63   9% 448.08   10% 528.94   10% 602.15   11% 707.99   13%
Depreciation Expense 46.68      1% 47.74    1% 49.18    1% 50.17    1% 52.19    1% 53.77    1% 32.63    1%
Operating Expenses 511.24     16% 560.43   15% 619.34   14% 692.90   15% 782.23   15% 877.04   17% 979.36   18%
(TCOS) Total Cost of Sales 1,913.33  60% 2,215.13 58% 2,463.45 56% 2,639.12 56% 2,875.52 56% 2,973.05 57% 3,160.06 58%
Operating Income (EBIT) 1,273.22  40% 1,633.01 42% 1,927.29 44% 2,061.89 44% 2,230.05 44% 2,266.97 43% 2,291.69 42%
Taxes 369.23     12% 473.57   12% 558.91   13% 597.95   13% 646.72   13% 657.42   13% 664.59   12%
Net Income 903.99     28% 1,159.44 30% 1,368.37 31% 1,463.94 31% 1,583.34 31% 1,609.55 31% 1,627.10 30%
Pro-Forma Balance Sheet (2013-2018) 1st 6 of 18 years 
Company:	  Amgen,	  CNS	  Market	  Segment,	  Traumatic	  Brain	  Injury	  Treatment	  –	  Strategy:	  CONCUSSYN	  
By:	  Justin	  Deats 
Source:	  	  Seshan,	  V.	  PH.D.	  Strategic	  Management,	  Financial	  Analysis,	  and	  Cash	  Flow.	  Thirteenth	  Edition.	  Cengage,	  Mason,	  OH.,	  Book	  and	  CD-­‐Rom,	  Pages	  168-­‐173.	  2013.	  
Item 2013 %TA 2014 %TA 2015 %TA 2016 %TA 2017 %TA 2018 %TA
$MM Assets
Current Assets:
Cash 273.21    42% 435.70   52% 672.40   62% 812.94   65% 975.43   69% 1,128.74   71%
Accounts Receivables -         0% -        0% -        0% -        0% -        0% -         0%
Inventories -         0% -        0% -        0% -        0% -        0% -         0%
Total Current Assets 273.21    42% 435.70   52% 672.40   62% 812.94   65% 975.43   69% 1,128.74   71%
Property, Plant & Equipment 400.00    61% 448.00   54% 492.80   45% 537.15   43% 574.75   41% 620.73     39%
Less: Accumulated Depreciation 22.22      3% 47.11     6% 74.49     7% 104.33   8% 136.26   10% 170.75     11%
Net P,P & E  Assets: 377.78    58% 400.89   48% 418.31   38% 432.82   35% 438.49   31% 449.99     29%
Total Assets 650.99    100% 836.59   100% 1,090.71 100% 1,245.76 100% 1,413.92 100% 1,578.73   100%
Liabilities
Current Liabilities:
Accounts Payable -         0% 2.00      0% 3.20      0% 3.00      0% 2.60      0% 4.00        0%
Other Liabilities -         0% 4.00      0% 6.08      1% 5.40      0% 4.42      0% 6.80        0%
Total Current Liabilities: -         0% 6.00      1% 9.28      1% 8.40      1% 7.02      0% 10.80      1%
Net Working Capital (NWC) 273.21    429.70   51% 663.12   61% 804.54   65% 968.41   68% 1,117.94   71%
Long-Term Liabilities:
Long-Term Debt -         0% -        0% -        0% -        0% -        0% -         0%
Total Liabilities -         0% 6.00      1% 9.28      1% 8.40      1% 7.02      0% 10.80      1%
Stockholders' Equity
Stockholders' Equity:
Retained Earnings from Strategy 650.99    100% 830.59   99% 1,081.43 99% 1,237.36 99% 1,406.90 100% 1,567.93   99%
Total Stockholders' Equity 650.99    100% 830.59   99% 1,081.43 99% 1,237.36 99% 1,406.90 100% 1,567.93   99%
Total Liabilities & Stockholders' Equity: 650.99    100% 836.59   100% 1,090.71 100% 1,245.76 100% 1,413.92 100% 1,578.73   100%
Pro-Forma Balance Sheet (2019-2024) 2nd 6 of 18 years 
Company:	  Amgen,	  CNS	  Market	  Segment,	  Traumatic	  Brain	  Injury	  Treatment	  –	  Strategy:	  CONCUSSYN	  
By:	  Justin	  Deats 
Source:	  	  Seshan,	  V.	  PH.D.	  Strategic	  Management,	  Financial	  Analysis,	  and	  Cash	  Flow.	  Thirteenth	  Edition.	  Cengage,	  Mason,	  OH.,	  Book	  and	  CD-­‐Rom,	  Pages	  168-­‐173.	  2013.	  
Item 2019 %TA 2020 %TA 2021 %TA 2022 %TA 2023 %TA 2024 %TA
$MM Assets
Current Assets:
Cash 1,324.56 58% 1,456.23 54% 1,553.40 49% 1,628.43 44% 1,698.56 40% 1,765.53 36%
Accounts Receivable $MM 210.14    9% 342.43    13% 506.10   16% 681.27    19% 894.44    21% 1,159.21 24%
Inventories 286.56    13% 466.95    17% 690.13   22% 929.01    25% 1,219.69 29% 1,580.74 32%
Total Current Assets 1,821.26 80% 2,265.61 83% 2,749.63 86% 3,238.71 88% 3,812.69 90% 4,505.48 92%
Property, Plant & Equipment 664.18    29% 697.39    26% 725.29   23% 754.30    21% 776.93    18% 808.01    17%
Less: Accumulated Depreciation 207.65    9% 246.39    9% 286.68   9% 328.59    9% 371.75    9% 416.64    9%
Net P,P & E Assets: 456.54    20% 451.00    17% 438.61   14% 425.71    12% 405.18    10% 391.37    8%
Total Assets 2,277.80 100% 2,716.61 100% 3,188.23 100% 3,664.42 100% 4,217.87 100% 4,896.84 100%
Liabilities
Current Liabilities:
Accounts Payable 143.28    6% 233.47    9% 345.07   11% 464.50    13% 609.85    14% 790.37    16%
Other Liabilities 233.55    10% 396.91    15% 586.61   18% 715.34    20% 811.09    19% 1,027.48 21%
Total Current Liabilities: 376.82    17% 630.38    23% 931.68   29% 1,179.84 32% 1,420.94 34% 1,817.85 37%
Net Working Capital (NWC) 1,444.44 63% 1,635.23 60% 1,817.95 57% 2,058.87 56% 2,391.75 57% 2,687.63 55%
Long-Term Liabilities:
Long-Term Debt -        -     -        -     -        -     -        -     -        -    -        -     
Total Liabilities 376.82    17% 630.38    23% 931.68   29% 1,179.84 32% 1,420.94 34% 1,817.85 37%
Stockholders' Equity
Stockholders' Equity:
Retained Earnings from Strategy 1,900.98 83% 2,086.23 77% 2,256.56 71% 2,484.58 68% 2,796.93 66% 3,078.99 63%
Total Stockholders' Equity 1,900.98 83% 2,086.23 77% 2,256.56 71% 2,484.58 68% 2,796.93 66% 3,078.99 63%
Total Liabilities & Stockholders' Equity: 2,277.80 100% 2,716.61 100% 3,188.23 100% 3,664.42 100% 4,217.87 100% 4,896.84 100%
Pro-Forma Balance Sheet (2025-2031) Last 7 of 18 years 
Company:	  Amgen,	  CNS	  Market	  Segment,	  Traumatic	  Brain	  Injury	  Treatment	  –	  Strategy:	  CONCUSSYN	  
By:	  Justin	  Deats 
Source:	  	  Seshan,	  V.	  PH.D.	  Strategic	  Management,	  Financial	  Analysis,	  and	  Cash	  Flow.	  Thirteenth	  Edition.	  Cengage,	  Mason,	  OH.,	  Book	  and	  CD-­‐Rom,	  Pages	  168-­‐173.	  2013.	  
Item 2025 %TA 2026 %TA 2027 %TA 2028 %TA 2029 %TA 2030 %TA 2031 %TA
$MM Assets
Current Assets:
Cash 1,822.32   34% 1,966.14   33% 2,190.37 34% 2,383.87 35% 2,507.21 35% 2,563.08 34% 2,751.88 35%
Accounts Receivable 1,402.08   26% 1,538.07   25% 1,658.41 26% 1,768.43 26% 1,896.54 26% 1,984.32 26% 2,086.31 26%
Inventories 1,832.98   34% 2,179.18   36% 2,234.09 35% 2,379.03 35% 2,568.91 35% 2,701.38 36% 2,793.55 35%
Total Current Assets 5,057.38   93% 5,683.39   94% 6,082.87 95% 6,531.33 96% 6,972.66 96% 7,248.78 97% 7,631.74 97%
Property, Plant & Equipment 840.33     15% 865.54     14% 891.50   14% 909.33   13% 945.71   13% 974.08   13% 993.56   13%
Less: Accumulated Depreciation 463.33     9% 511.07     8% 560.25   9% 610.42   9% 662.62   9% 716.39   10% 749.02   10%
Net P,P & E Assets: 377.00     7% 354.47     6% 331.25   5% 298.91   4% 283.09   4% 257.69   3% 244.54   3%
Total Assets 5,434.38   100% 6,037.86   100% 6,414.12 100% 6,830.24 100% 7,255.75 100% 7,506.47 100% 7,876.28 100%
Liabilities
Current Liabilities:
Accounts Payable 955.97     18% 1,154.44   19% 1,317.22 21% 1,410.30 21% 1,531.67 21% 1,572.01 21% 1,635.52 21%
Other Liabilities 1,242.75   23% 1,500.78   25% 1,712.39 27% 1,833.39 27% 2,037.12 28% 2,043.61 27% 2,126.18 27%
Total Current Liabilities: 2,198.72   40% 2,655.22   44% 3,029.61 47% 3,243.69 47% 3,568.80 49% 3,615.61 48% 3,761.70 48%
Net Working Capital (NWC) 2,858.66   53% 3,028.17   50% 3,053.26 48% 3,287.64 48% 3,403.86 47% 3,633.17 48% 3,870.04 49%
Long-Term Liabilities:
Long-Term Debt -          -  -         -  -        -  -        -  -        -  -        -  -        -  
Total Liabilities 2,198.72   40% 2,655.22   44% 3,029.61 47% 3,243.69 47% 3,568.80 49% 3,615.61 48% 3,761.70 48%
Stockholders' Equity
Stockholders' Equity:
Retained Earnings from Strategy 3,235.66   60% 3,382.64   56% 3,384.51 53% 3,586.55 53% 3,686.95 51% 3,890.86 52% 4,114.58 52%
Total Stockholders' Equity 3,235.66   60% 3,382.64   56% 3,384.51 53% 3,586.55 53% 3,686.95 51% 3,890.86 52% 4,114.58 52%
Total Liabilities & Stockholders' Equity: 5,434.38   100% 6,037.86   100% 6,414.12 100% 6,830.24 100% 7,255.75 100% 7,506.47 100% 7,876.28 100%
Schedule of R&D Expenditures (2013-2031) 18 years 
Company:	  Amgen,	  CNS	  Market	  Segment,	  Traumatic	  Brain	  Injury	  Treatment	  –	  Strategy:	  CONCUSSYN	  
By:	  Justin	  Deats 
Source:	  	  Seshan,	  V.	  PH.D.	  Strategic	  Management,	  Financial	  Analysis,	  and	  Cash	  Flow.	  Thirteenth	  Edition.	  Cengage,	  Mason,	  OH.,	  Book	  and	  CD-­‐Rom,	  Page	  174.	  2013.	  
Expenditures for R&D Percentage Change R&D as % of Net Sales
Year ($MM)
2013 122.84$                 0%
2014 125.11$                 2% 0%
2015 128.53$                 3% 0%
2016 133.08$                 4% 0%
2017 134.21$                 1% 0%
2018 137.63$                 3% 0%
2019 142.18$                 3% 30%
2020 166.06$                 17% 21%
2021 192.22$                 16% 17%
2022 219.52$                 14% 14%
2023 249.08$                 13% 12%
2024 283.21$                 14% 11%
2025 315.19$                 11% 10%
2026 346.94$                 10% 9%
2027 391.63$                 13% 9%
2028 448.08$                 14% 10%
2029 528.94$                 18% 10%
2030 602.15$                 14% 11%
2031 707.99$                 18% 13%
Permanent Investment Worksheet (2013-2031) 18 years 
Company:	  Amgen,	  CNS	  Market	  Segment,	  Traumatic	  Brain	  Injury	  Treatment	  –	  Strategy:	  CONCUSSYN	  
By:	  Justin	  Deats 
Source:	  	  Seshan,	  V.	  PH.D.	  Strategic	  Management,	  Financial	  Analysis,	  and	  Cash	  Flow.	  Thirteenth	  Edition.	  Cengage,	  Mason,	  OH.,	  Book	  and	  CD-­‐Rom,	  Page	  175.	  2013.	  
Property, Total Change in Change in
Year Net Sales Plant & R & D Permanent Permanent Working Working
Equipment Investment Investment Capital Capital
2013 -                400.00 122.84 522.84 522.84 273         273          
2014 -$              448.00 125.11 573.11 50.27 429.70 156.49      
2015 -$              492.80 128.53 621.33 48.22 663.12 233.42      
2016 -$              537.15 133.08 670.23 48.90 804.54 141.42      
2017 -$              574.75 134.21 708.96 38.73 968.41 163.87      
2018 -$              620.73 137.63 758.36 49.40 1117.94 149.53      
2019 477.60$          664.18 142.18 806.36 48.00 1444.44 326.50      
2020 778.25$          697.39 166.06 863.45 57.09 1635.23 190.79      
2021 1,150.22$       725.29 192.22 917.51 54.06 1817.95 182.72      
2022 1,548.35$       754.30 219.52 973.82 56.31 2058.87 240.92      
2023 2,032.82$       776.93 249.08 1026.01 52.19 2391.75 332.88      
2024 2,634.56$       808.01 283.21 1091.22 65.21 2687.63 295.88      
2025 3,186.55$       840.33 315.19 1155.52 64.30 2858.66 171.03      
2026 3,848.15$       865.54 346.94 1212.48 56.96 3028.17 169.51      
2027 4,390.74$       891.50 391.63 1283.13 70.66 3053.26 25.09        
2028 4,701.00$       909.33 448.08 1357.41 74.28 3287.64 234.38      
2029 5,105.57$       945.71 528.94 1474.65 117.23 3403.86 116.23      
2030 5,240.02$       974.08 602.15 1576.23 101.58 3633.17 229.30      
2031 5,451.75$       993.56 707.99 1701.55 125.32 3870.04 236.87      
Cash Flow Projections (2013-2031) 18 years 
Company:	  Amgen,	  CNS	  Market	  Segment,	  Traumatic	  Brain	  Injury	  Treatment	  –	  Strategy:	  CONCUSSYN	  
By:	  Justin	  Deats 
Source:	  	  Seshan,	  V.	  PH.D.	  Strategic	  Management,	  Financial	  Analysis,	  and	  Cash	  Flow.	  Thirteenth	  Edition.	  Cengage,	  Mason,	  OH.,	  Book	  and	  CD-­‐Rom,	  Page	  176.	  2013.	  
Cumulative
Change in Change in Net Discounted Discounted 
Permanent Working Cash Net Cumulative Net Cash Cash Flow @
Year Investment Capital Outflow Depreciation Net Income Cash Inflow Cash Flow Cash Flow Flow @ 10% 10%
   (NWC)2 - (Change in Permanent
P,P&E+R&D  (NWC)1 Investment + (Straight-Line) (Depreciation + (Cash Inflow- Algebraic Sum 
Change in Change in Net Net Income) Cash Outflow) of Net Cash 
NWC Working Capital) Flow[NCF]
2013 522.84 522.84                  22.22          (160.63)             (138.41)           (661.25)          (661.25)          (661.25)         (661.25)          
2014 50.27 156.49            206.76                  24.89          (168.88)             (143.99)           (350.75)          (1,012.00)        (318.86)         (980.11)           
2015 48.22 233.42            281.64                  27.38          (177.00)             (149.62)           (431.26)          (1,443.26)        (356.41)         (1,336.53)        
2016 48.90 141.42            190.32                  29.84          (188.07)             (158.23)           (348.55)          (1,791.81)        (261.87)         (1,598.40)        
2017 38.73 163.87            202.60                  31.93          (193.83)             (161.90)           (364.50)          (2,156.31)        (248.96)         (1,847.36)        
2018 49.40 149.53            198.93                  34.49          (204.54)             (170.05)           (368.98)          (2,525.29)        (229.11)         (2,076.47)        
2019 48.00 326.50            374.50                  36.90          56.86               93.76             (280.74)          (2,806.04)        (158.47)         (2,234.94)        
2020 57.09 190.79            247.88                  38.74          131.50              170.25            (77.63)           (2,883.67)        (39.84)           (2,274.78)        
2021 54.06 182.72            236.78                  40.29          260.50              300.80            64.02            (2,819.65)        29.86            (2,244.91)        
2022 56.31 240.92            297.23                  41.91          424.40              466.31            169.08           (2,650.57)        71.71            (2,173.21)        
2023 52.19 332.88            385.07                  43.16          605.41              648.57            263.50           (2,387.07)        101.59          (2,071.61)        
2024 65.21 295.88            361.08                  44.89          787.68              832.57            471.49           (1,915.58)        165.25          (1,906.36)        
2025 64.30 171.03            235.34                  46.68          903.99              950.67            715.34           (1,200.25)        227.93          (1,678.43)        
2026 56.96 169.51            226.47                  47.74          1,159.44            1,207.18          980.71           (219.53)          284.08          (1,394.35)        
2027 70.66 25.09              95.75                   49.18          1,368.37            1,417.56          1,321.81        1,102.28        348.07          (1,046.28)        
2028 74.28 234.38            308.66                  50.17          1,463.94            1,514.11          1,205.46        2,307.73        288.58 (757.70)          
2029 117.23 116.23            233.46                  52.19          1,583.34            1,635.53          1,402.07        3,709.80        305.13 (452.57)          
2030 101.58 229.30            330.88                  53.77          1,609.55            1,663.32          1,332.44        5,042.24        263.62 (188.96)          
2031 125.32 236.87            362.19                  32.63          1,627.10            1,659.73          1,297.54        6,339.78        233.37 44.42             
Exhibit 3.2. : Cash Flow Projection Graph (2013-2031) 18 years 
Company:	  Amgen,	  CNS	  Market	  Segment,	  Traumatic	  Brain	  Injury	  Treatment	  –	  Strategy:	  CONCUSSYN	  
By:	  Justin	  Deats 
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